Acutus Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CARLSBAD, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted equity awards on November 1, 2023 that were approved by the Compensation Committee of its Board of Directors under Company’s 2022 Inducement Equity Incentive Plan, as a material inducement to employment to 5 individuals hired by Acutus in October 2023. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Related news for (AFIB)
- Acutus Medical Reports Full Year 2024 Financial Results
- Acutus Medical Announces Operational Downsizing
- Acutus Medical Reports Third Quarter and Year-To-Date 2024 Financial Results
- Acutus Medical Reports Second Quarter and Year-To-Date 2024 Financial Results
- Acutus Medical Reports First Quarter 2024 Financial Results